J. R. Rop, . Kma, . Wt, . Tw, . Gs et al., NFS and TSvdW contributed to study monitoring, 2019.

. Who and . Buruli, , 2019.

, Fourth WHO report in neglected tropical disease; integrating NTD into global health and development, vol.17, 2019.

H. Simpson, K. Deribe, and E. N. Tabah, Mapping the global distribution of Buruli ulcer: a systematic review with evidence consensus, Lancet Glob Health, vol.7, pp.912-934, 2019.

P. Johnson, Buruli ulcer: here today but where tomorrow?, Lancet Glob Health, vol.7, pp.821-843, 2019.

D. Yeboahmanu, S. Y. Aboagye, and P. Asare, Laboratory confirmation of Buruli ulcer cases in Ghana, PLoS Negl Trop Dis, vol.12, p.6560, 2008.

D. T. Beeres, J. Horstman, and P. Van-der-tak, The paediatric participation scale measuring participation restrictions among former Buruli ulcer patients under the age of 15 in Ghana and Benin: development and first validation results, PLoS Negl Trop Dis, vol.13, p.7273, 2019.

A. Tai, E. Athan, N. D. Friedman, A. Hughes, A. Walton et al., Increased severity and spread of Mycobacterium ulcerans, southeastern Australia, Emerg Infect Dis, vol.24, pp.58-64, 2018.

M. J. Loftus, E. L. Tay, and M. Globan, Epidemiology of Buruli ulcer infections, vol.24, pp.1988-97, 2018.

S. Etuaful, B. Carbonnelle, and J. Grosset, Efficacy of the combination rifampinstreptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans, Antimicrob Agents Chemother, vol.49, pp.3182-86, 2005.

Y. Stienstra, W. Van-der-graaf, K. Asamoa, and T. S. Van-der-werf, Beliefs and attitudes toward Buruli ulcer in Ghana, Am J Trop Med Hyg, vol.67, pp.207-220, 2002.

Y. Stienstra, M. Van-roest, and M. J. Van-wezel, Factors associated with functional limitations and subsequent employment or schooling in Buruli ulcer patients, Trop Med Int Health, vol.10, pp.1251-57, 2005.

Q. B. Vincent, M. F. Ardant, and A. Adeye, Clinical epidemiology of laboratoryconfirmed Buruli ulcer in Benin: a cohort study, Lancet Glob Health, vol.2, pp.422-452, 2014.

F. S. Sarfo, R. Phillips, and K. Asiedu, Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease, Antimicrob Agents Chemother, vol.54, pp.3678-85, 2010.

W. A. Nienhuis, Y. Stienstra, and W. A. Thompson, Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial, Lancet, vol.375, pp.664-72, 2010.

S. Klis, Y. Stienstra, R. O. Phillips, K. M. Abass, W. Tuah et al., Long term streptomycin toxicity in the treatment of Buruli ulcer: followup of participants in the BURULICO drug trial, PLoS Negl Trop Dis, vol.8, p.2739, 2014.

B. Ji, A. Chauffour, J. Robert, S. Lefranc?ois, and V. Jarlier, Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice, Antimicrob Agents Chemother, vol.51, pp.3737-3776, 2007.

D. Almeida, P. J. Converse, Z. Ahmad, K. E. Dooley, E. L. Nuermberger et al., Activities of rifampin, rifapentine and clarithromycin alone and in combination against Mycobacterium ulcerans disease in mice, PLoS Negl Trop Dis, vol.5, p.933, 2011.

R. O. Phillips, F. S. Sarfo, and M. K. Abass, Clinical and bacteriological efficacy of rifampinstreptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease, Antimicrob Agents Chemother, vol.58, pp.1161-66, 2014.

A. Chauty, M. F. Ardant, and L. Marsollier, Oral treatment for Mycobacterium ulcerans infection: results from a pilot study in Benin, Clin Infect Dis, vol.52, pp.94-96, 2011.

K. F. Schulz, D. G. Altman, D. Moher, and . Consort, statement: updated guidelines for reporting parallel group randomised trials, PLoS Med, vol.7, p.1000251, 2010.

, WHO. Facilities involved in Buruli ulcer clinical trial 2012-2015 in Ghana and Benin, vol.17, 2012.

K. M. Abass, T. S. Van-der-werf, and R. O. Phillips, Buruli ulcer control in a highly endemic district in Ghana: role of communitybased surveillance volunteers, Am J Trop Med Hyg, vol.92, pp.115-132, 2015.

Y. T. Barogui, G. E. Sopoh, and R. C. Johnson, Contribution of the community health volunteers in the control of Buruli ulcer in Bénin, PLoS Negl Trop Dis, vol.8, p.3200, 2014.

K. H. Herbinger, O. Adjei, and N. Y. Awuaboateng, Comparative study of the sensitivity of different diagnostic methods for the laboratory diagnosis of Buruli ulcer disease, Clin Infect Dis, vol.48, pp.1055-64, 2009.

M. Eddyani, C. Lavender, and W. B. De-rijk, Multicenter external quality assessment program for PCR detection of Mycobacterium ulcerans in clinical and environmental specimens, PLoS One, vol.9, p.89407, 2014.

W. A. Nienhuis, Y. Stienstra, and K. M. Abass, Paradoxical responses after start of antimicrobial treatment in Mycobacterium ulcerans infection, Clin Infect Dis, vol.54, pp.519-545, 2012.

A. Velink, R. J. Woolley, and R. O. Phillips, Former buruli ulcer patients' experiences and wishes may serve as a guide to further improve buruli ulcer management, PLoS Negl Trop Dis, vol.10, p.5261, 2016.

K. A. Ampah, P. Asare, and D. Binnah, Burden and historical trend of buruli ulcer prevalence in selected communities along the Offin River of Ghana, PLoS Negl Trop Dis, vol.10, p.4603, 2016.

E. G. Anagonou, R. C. Johnson, and Y. T. Barogui, Decrease in Mycobacterium ulcerans disease (Buruli ulcer) in the Lalo District of Bénin (west Africa), BMC Infect Dis, vol.19, p.247, 2019.

A. C. Wadagni, Y. T. Barogui, and R. C. Johnson, Delayed versus standard assessment for excision surgery in patients with Buruli ulcer in Benin: a randomised controlled trial, Lancet Infect Dis, vol.18, pp.650-56, 2018.

N. D. Friedman, E. Athan, A. L. Walton, O. 'brien, and D. P. , Increasing experience with primary oral medical therapy for Mycobacterium ulcerans disease in an Australian cohort, Antimicrob Agents Chemother, vol.60, pp.2692-95, 2016.

D. P. O'brien, D. Friedman, A. Hughes, A. Walton, and E. Athan, Antibiotic complications during the treatment of Mycobacterium ulcerans disease in Australian patients, Intern Med J, vol.47, pp.1011-1030, 2017.

S. Klis, R. A. Kingma, W. Tuah, T. S. Van-der-werf, and Y. Stienstra, Clinical outcomes of Ghanaian Buruli ulcer patients who defaulted from antimicrobial therapy, Trop Med Int Health, vol.21, pp.1191-96, 2016.

D. P. O'brien, N. D. Friedman, R. Cowan, A. Walton, and E. Athan, Six versus eight weeks of antibiotics for small Mycobacterium ulcerans lesions in Australian patients, Clin Infect Dis, 2019.

J. Alffenaar, W. A. Nienhuis, and F. De-velde, Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection, Antimicrob Agents Chemother, vol.54, pp.3878-83, 2010.

L. Marsollier, N. Honoré, and P. Legras, Isolation of three Mycobacterium ulcerans strains resistant to rifampin after experimental chemotherapy of mice, Antimicrob Agents Chemother, vol.47, pp.1228-1260, 2003.

M. Jansson, M. Beissner, and R. O. Phillips, Comparison of two assays for molecular determination of rifampin resistance in clinical samples from patients with Buruli ulcer disease, J Clin Microbiol, vol.52, pp.1246-1295, 2014.

P. J. Converse, D. V. Almeida, and R. Tasneen, Shortercourse treatment for Mycobacterium ulcerans disease with highdose rifamycins and clofazimine in a mouse model of Buruli ulcer, PLoS Negl Trop Dis, vol.12, p.6728, 2018.

P. J. Converse, D. V. Almeida, S. Tyagi, J. Xu, and E. L. Nuermberger, Shortening buruli ulcer treatment with combination therapy targeting the respiratory chain and exploiting Mycobacterium ulcerans gene decay, Antimicrob Agents Chemother, vol.63, pp.426-445, 2019.

N. Scherr, R. Bieri, and S. S. Thomas, Targeting the Mycobacterium ulcerans cytochrome bc 1 :aa 3 for the treatment of Buruli ulcer, Nat Commun, vol.9, pp.5370-79, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01975358